Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Suspended 2Recruiting 2Active not recruiting 2Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Carcinoma 1

Interventions

pembrolizumab 27Cisplatin 17Nivolumab 14Cyclophosphamide 14Carboplatin 13Radiation 12Paclitaxel 12Doxorubicin 11Radiotherapy 10Radiotherapy, Intensity-Modulated 9Cytarabine 9Vincristine 8Magnetic Resonance Spectroscopy 8Docetaxel 8Bevacizumab 8Radiosurgery 7Leucovorin 7Fluorouracil 7Etoposide 7Specimen Handling 6Prednisone 6Pemetrexed 6Irinotecan 6Injections 6Gemcitabine 6Dexamethasone 6venetoclax 5tislelizumab 5fludarabine 5enzalutamide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × (225)Ac-DOTA-c(RGDyK) × 30 days × Clear all
NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡